Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
7.70
+0.04 (0.52%)
Jul 10, 2026, 4:00 PM EDT - Market closed
Instil Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
52.22M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 53.48M |
| Metagenomi Therapeutics | 22.33M |
| Immutep | 5.28M |
| CervoMed | 2.09M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| INmune Bio | 50.00K |
TIL News
- 2 months ago - Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Instil Bio downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 6 months ago - Baird downgrades Instil Bio on discontinuation of AXN-2510 - TheFly
- 6 months ago - Instil Bio downgraded to Neutral from Outperform at Baird - TheFly
- 6 months ago - Instil Bio’s Axion discontinues clinical development of AXN-2510 - TheFly
- 6 months ago - Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco - GlobeNewsWire
- 8 months ago - Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year - TheFly